Seres Therapeutics Inc. (MCRB)
MCRB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/0001193125-26-103276-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MCRB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001609809 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $789K |
| Net income | $5.7M |
| Operating income | -$94.0M |
| Net margin | 721.9% |
| Operating margin | -11910.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $45.8M |
| Total assets | $138.2M |
| P/E (computed) | 2.5× |
| P/S (computed) | 18.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-04 |
| Cash and burn | $17.5M cash; operating cash flow -$16.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 10,195,031 (2026-11-02); 9,046,519 a year earlier; 129,257,199 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-04-22 | Source 2025-04-22 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $55K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $593K | -$16.3M | -$10.5M | $17.5M | No debt tags | $2.1M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $736K | $4.6M | -$22.4M | $15.6M | No debt tags | $1.9M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $358K | -$19.9M | -$16.4M | $29.8M | No debt tags | $1.1M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $438K | -$15.3M | -$14.7M | $45.8M | No debt tags | $789K | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $351K | $8.2M | $2.2M | $47.6M | No debt tags | $351K | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $0 | -$19.9M | -$13.3M | $45.4M | No debt tags | $0 | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $0 | $32.7M | $26.9M | $58.8M | No debt tags | $0 | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $0 | -$15.6M | -$38.9M | $30.8M | No debt tags | $0 | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-13 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 724 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -29.3% |
| 1 month | -44.7% |
| 3 months | -68.8% |
| Year to date | -90.6% |
| 1 year | -91.6% |
| From 52-week high | -95.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
| MRKR | Marker Therapeutics Inc. | $0.8286 | -4.76% | $13.8M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier